1. Scrip
  2. >>New Products

Gilead HIV Sales Getting Boost From Switches To TAF-Based Combos

 
• By Joseph Haas

Eighty percent of patients who’ve received Genvoya so far are switched over from older Gilead regimens, while 10% have switched from non-Gilead drugs. In terms of cumulative prescriptions, the Genvoya launch is outpacing the launch of predecessor drug Stribild to date.

The future of Gilead Sciences Inc.’s HIV business depends on switching patients over to its newer HIV single-tablet regimens where the older Viread is replaced with the prodrug tenofovir alafenamide (TAF), and not only did it report strong starts in the third quarter, it has new evidence in hand that should help it convert patients from the old to the new.

In an interview with Scrip, Gilead’s VP-HIV Medical Affairs David Piontkowsky noted that at the recent 2016 Glasgow HIV meeting...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Aurobindo On Easier US Biosimilar Pathway, Zentiva Miss And Deal Strategy

 
• By Vibha Ravi

Do US FDA’s efforts at simplifying the biosimilar pathway create more competition and threaten Aurobindo Pharma's return on investments? Management speaks on this, biosimilar filing plans and deal strategy at the Q2 FY26 earnings call

Pipeline Watch: Four Approvals And Four Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Boehringer Sees Opportunities For Jascayd In Evolving China IPF Landscape

 
• By Xu Hu

Boehringer’s PDE4B inhibitor Jascayd was approved for IPF in China on Oct. 22, marking its second nod globally soon after the US. The German firm discusses with Scrip the opportunities and challenges in this market.

Akebia Abandons Non-Dialysis Trial For Vafseo On Likely Higher Costs

 
• By Manas Mishra

After yet another regulatory setback in its quest to bring Vafseo to non-dialysis dependent kidney disease patients in the US, Akebia said it would no longer conduct a planned Phase III trial for the commercially important population.

More from Scrip

Lilly’s Eloralintide Success Sets Bar For Amylin Rivals

 
• By Andrew McConaghie

The US pharma giant may have a best-in-class amylin agonist to go with incretin blockbuster Zepbound, but challengers could still go one better on safety and tolerability.

Bavarian Nordic Future Looks Bright Despite Failed Takeover Bid

 
• By Kevin Grogan

Even with Innosera's sweetened offers and a boardroom recommendation, the proposed acquisition could not clear the minimum 66.67% shareholder approval level.

Centessa’s Sleep Disorder Drug Shows Broad Potential But Faces Tough Competition

 
• By Sushmita Panda

Pivotal data next year will be key for the early-stage biotech as analysts remain divided on ORX750's potential.